KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Asset Writedowns and Impairment (2016 - 2024)

Teva Pharmaceutical Industries filings provide 16 years of Asset Writedowns and Impairment readings, the most recent being $679.0 million for Q1 2024.

  • On a quarterly basis, Asset Writedowns and Impairment rose 259.26% to $679.0 million in Q1 2024 year-over-year; TTM through Mar 2024 was $1.6 billion, a 36.53% decrease, with the full-year FY2023 number at $1.1 billion, down 55.95% from a year prior.
  • Asset Writedowns and Impairment hit $679.0 million in Q1 2024 for Teva Pharmaceutical Industries, up from $68.0 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $5.2 billion in Q3 2020 to a low of $28.0 million in Q3 2022.
  • Median Asset Writedowns and Impairment over the past 5 years was $227.0 million (2021), compared with a mean of $666.8 million.
  • Biggest five-year swings in Asset Writedowns and Impairment: surged 2433.66% in 2020 and later crashed 99.1% in 2021.
  • Teva Pharmaceutical Industries' Asset Writedowns and Impairment stood at $232.0 million in 2020, then dropped by 21.12% to $183.0 million in 2021, then skyrocketed by 689.62% to $1.4 billion in 2022, then crashed by 95.29% to $68.0 million in 2023, then surged by 898.53% to $679.0 million in 2024.
  • The last three reported values for Asset Writedowns and Impairment were $679.0 million (Q1 2024), $68.0 million (Q4 2023), and $48.0 million (Q3 2023) per Business Quant data.